Fecal Immunochemical Test: How It Works and What It Detects

The fecal immunochemical test, commonly called FIT, is a stool-based screening tool that detects hidden blood in your stool by targeting human hemoglobin with antibodies. Unlike older stool tests, it does not react to blood from food or animal sources, which makes it more specific to bleeding in your lower digestive tract. A large meta-analysis found FIT has an overall accuracy of about 95% for colorectal cancer, with pooled sensitivity around 79% and specificity around 94%.¹ That combination of a simple at-home collection and strong diagnostic performance is why FIT has become the most widely used non-invasive colorectal cancer screening method worldwide.

How FIT Works and Why It Replaced the Guaiac Test

For decades, colorectal cancer screening relied on guaiac-based fecal occult blood tests, which detect blood through a chemical reaction with heme, a component found in all hemoglobin, including from dietary red meat. That meant you had to follow dietary restrictions before the test, and false positives from food were common. FIT uses antibodies that bind specifically to human hemoglobin, so it ignores blood from the steak you ate last night. No dietary preparation is needed, and you only need to collect one sample rather than the multiple samples older tests required.²

The practical advantage translates directly into better cancer detection. A Cochrane systematic review comparing the two approaches in average-risk people found that guaiac tests caught about 39% of colorectal cancers, while FIT at a standard threshold caught roughly 65% to 76%, depending on the cutoff used. For precancerous growths known as advanced neoplasia, the gap was even wider: guaiac tests detected about 15%, while FIT caught 26% to 33%.³ That improvement in sensitivity, paired with less hassle for the person taking the test, is why screening programs around the world have largely switched to FIT.

What FIT Catches Well and What It Misses

FIT is strongest at detecting established colorectal cancers, especially those that have grown beyond the earliest stage. A large study examining sensitivity by tumor stage found that at the manufacturer-recommended cutoff, overall sensitivity for cancer was 85%. But that number hides a stark gap: sensitivity for the earliest-stage tumors (T1, confined to the inner lining of the colon) was only about 52%, compared with 79% to 93% for more advanced tumors.⁴ The reason is straightforward: small, early-stage growths bleed less, so they produce less hemoglobin in the stool for the antibodies to find.

Advanced adenomas, the precancerous polyps that screening most hopes to catch before they turn malignant, are FIT’s biggest blind spot. A systematic review found that single-test sensitivity for advanced adenomas was only about 40% at a standard threshold, and the authors stated clearly that sensitivity for these growths is low regardless of what threshold you use.⁵ A separate systematic review confirmed that while FIT detects the majority of cancers, it misses some cancers and most advanced adenomas on any single round.⁶

Location matters too. Cancers and polyps on the right side of the colon are harder for FIT to detect than those on the left side. One study found sensitivity for advanced neoplasia on the left side was 33%, dropping to 20% for right-sided lesions at the same specificity level.⁷ Blood from right-sided lesions has to travel the full length of the colon before reaching the stool, and hemoglobin degrades along the way. By the time the sample is collected, the hemoglobin concentration from a right-sided bleed can fall below the test’s detection threshold.⁸

Choosing a Threshold and What It Means for You

Quantitative FIT tests do not just return “positive” or “negative.” They measure the concentration of hemoglobin in your stool, reported in micrograms of hemoglobin per gram of feces. The screening program or lab then applies a cutoff: anything above that number counts as positive. Different countries and programs use different cutoffs, and where that line falls has real consequences for what gets caught and how many colonoscopies get ordered.

A large community-based study tracked how lowering the threshold changed outcomes. At a cutoff of 30 micrograms per gram, the program caught 66% of cancers. Dropping to 20 caught about 74%, and dropping further to 10 caught roughly 79%. But each step down also meant more positive results per cancer found: 43 positive tests per cancer at 30, rising to 85 at 10.⁹ Each of those positive results triggers a colonoscopy referral, so lowering the threshold catches more cancer at the cost of substantially more follow-up procedures. The sweet spot depends on the healthcare system’s capacity for colonoscopy and its appetite for false positives.

A head-to-head comparison of nine commercial FIT brands showed that when thresholds were adjusted to yield the same specificity, the different tests produced nearly identical sensitivities for advanced neoplasia. At a specificity of 97%, for instance, all nine brands detected between 21% and 24% of advanced neoplasia.¹⁰ The differences between brands matter less than the threshold your screening program chooses.

FIT Versus Colonoscopy

The question many people have is whether FIT is “as good as” colonoscopy. Colonoscopy directly visualizes the entire colon and can remove polyps on the spot, which makes it the gold standard for a single screening event. But FIT has a different strategy: it is repeated regularly, typically every year or every two years, and the cumulative effect of repeated testing closes the gap.

A randomized trial reported in The Lancet directly compared a FIT-based program against colonoscopy-based screening for colorectal cancer mortality over ten years. The FIT program was non-inferior: colorectal cancer death rates were 0.24% in the FIT group and 0.22% in the colonoscopy group, a difference that was not statistically meaningful.¹¹ The key insight is that a program of repeated FIT, where people who test positive get colonoscopy, achieves comparable mortality reduction to screening everyone with colonoscopy once.

A population-based study further illustrated the value of sticking with the program. Among people who had completed five or more FIT rounds over a decade, the odds of developing colorectal cancer were roughly halved compared to those who had never been screened. Even a single FIT reduced the odds by about 19%, but the benefit grew with each additional round.¹² The catch is that you actually have to keep doing it. A single FIT missed and never repeated loses much of its protective value.

FIT Versus Stool DNA Tests

Multitarget stool DNA tests (often marketed under the brand name Cologuard in the United States) combine FIT hemoglobin detection with molecular markers for abnormal DNA shed by cancer or precancerous cells. A meta-analysis of diagnostic accuracy found that the stool DNA test had a combined sensitivity of 89% for colorectal cancer compared to 76% for FIT alone, and 51% for advanced adenomas compared to 25% for FIT.¹³ So the DNA test is more sensitive in a single round.

But that higher sensitivity comes with lower specificity: the DNA test’s overall specificity for cancer was about 91% compared to FIT’s 94%, meaning more false positives and more unnecessary colonoscopies. An independent comparison that set both tests to the same specificity found FIT’s cancer sensitivity rose to about 97%, actually exceeding the DNA test’s 92%, and FIT also detected more large polyps at that matched specificity.¹⁴ The DNA test is also recommended every three years rather than annually, costs substantially more per test, and requires you to collect an entire bowel movement rather than swipe a small sample. For many screening programs, FIT’s combination of low cost, simplicity, and annual repetition makes it the preferred first-line option.

How to Handle Your Sample

Because FIT detects hemoglobin, and hemoglobin degrades over time, how you handle the sample between collection and lab analysis matters. The main enemies are heat and delay. One study found that at room temperature, hemoglobin in FIT samples dropped significantly by day three in some buffer formulations, while refrigerated samples stayed more stable.¹⁵ Newer buffer formulations have improved stability: one evaluation showed hemoglobin stayed above 80% of its initial reading for about 20 days at room temperature in an updated buffer, compared to only six days in the original formulation.¹⁶

In real-world conditions, a study of one FIT brand with a newer buffer found that delays of up to seven days at normal indoor temperatures did not significantly change positivity rates or detection rates for cancer and advanced adenomas. However, at a constant 30 degrees Celsius, hemoglobin dropped by about 20% after a week.¹⁷ The practical advice: return your sample promptly, and if it is summer or you live somewhere hot, refrigerate the completed kit until you can get it to the lab or mail it. Do not leave it in a hot car or on a sunny windowsill.

Common Difficulties With Collection

FIT collection is simpler than many people expect, but it is not difficulty-free. A study comparing five different FIT brands found that about half of participants reported no difficulty at all with one card-based design, and roughly two-thirds had no trouble with the liquid-vial designs. Among those who did struggle, the most common complaints were messiness (about a fifth of users), a collection window that felt too small, and confusion about which cap to open on vials with caps on both ends.¹⁸ People who perceived the process as difficult were significantly more likely to make collection errors.

The good news is that imperfect collection does not necessarily ruin the test. A study that deliberately simulated common instruction violations found that inserting the probe only once (instead of the recommended multiple insertions) or not checking if the probe was fully loaded reduced hemoglobin readings, but the impact on diagnostic performance was generally small. Interestingly, putting too much stool into the tube actually increased hemoglobin readings and improved cancer detection slightly, at a small cost to specificity.¹⁹ So while following the instructions is ideal, the test is fairly forgiving of minor mistakes.

Labs do reject some samples outright. A cohort study of rejected FIT kits found that sampling errors were the most common cause of rejection, followed by expired specimens, missing collection dates, and incomplete patient information.²⁰ Writing the date on the label and making sure the sample is actually on the collection device are the basics that prevent rejection.

Do Medications Cause False Positives?

This is a question that comes up constantly, especially among people who take aspirin or blood thinners daily. The answer from the research is mixed and depends on what you mean by “false positive.” A systematic review and meta-analysis found that aspirin, antiplatelet agents, and oral anticoagulants significantly lowered the positive predictive value of FIT for advanced colorectal neoplasia, meaning a higher proportion of positive results in people on these drugs turned out to be false alarms.²¹

However, a separate systematic review reached a different conclusion, finding that the positive predictive value for advanced neoplasia was not significantly different between users and non-users of oral anticoagulants or aspirin and NSAIDs. The authors concluded FIT accuracy is not meaningfully affected by these medications.²² The discrepancy likely comes from differences in how the studies were selected and analyzed. In practice, most screening guidelines do not tell you to stop blood thinners before doing a FIT. If your test comes back positive while you are on anticoagulants, you will still be referred for colonoscopy, and the colonoscopy will settle whether anything is actually there.

What Happens After a Positive FIT

A positive FIT is not a cancer diagnosis. It means hemoglobin was detected above the threshold, and the next step is colonoscopy to find out why. The most common findings at follow-up colonoscopy are polyps of various sizes, many of which are benign or only mildly precancerous. Cancer is found in a minority of positive-FIT colonoscopies.

Timing of that follow-up colonoscopy matters a great deal. A systematic review found that when colonoscopy was delayed beyond nine months after a positive FIT, the odds of finding colorectal cancer were substantially higher than when colonoscopy happened within the first month. The two largest studies in the review reported adjusted odds ratios of 1.75 and 1.48 for cancer diagnosis with delays beyond nine months. Even more concerning, those studies also found significantly higher odds of the cancer being diagnosed at an advanced stage, with adjusted odds ratios of 2.79 and 1.55 for stage III or IV disease.²³ A positive FIT sitting in a drawer for months is one of the ways screening fails to help.

Why People Do and Do Not Complete the Test

FIT’s advantage over colonoscopy is supposed to be that more people actually do it. A colonoscopy requires bowel prep, sedation, a trip to a facility, and someone to drive you home. FIT arrives in the mail or gets handed to you at a clinic visit. But participation is far from universal. A survey of people who received FIT kits found that among non-users, about 60% cited discomfort, disgust, or embarrassment as reasons for not completing it. A third thought it was unnecessary, and about 15% reported fatalism or fear about what the test might find.²⁴

People who did complete the test were heavily influenced by their belief that their medical team considered screening important: about 89% of consistent users reported this belief, compared with only 54% of non-users. Among people who converted from previous non-use to completing a FIT, nearly half admitted doing it out of guilt.²⁵ A separate pragmatic trial found that previous FIT screening experience, age over 65, not smoking, and recent receipt of other preventive care like flu shots or mammograms all predicted higher completion rates.²⁶ Simply sending a reminder letter after the initial invitation increased participation by about 12% in the first round and up to 10% in subsequent rounds.²⁷

Cost-Effectiveness

FIT is inexpensive per test, typically costing a fraction of what a colonoscopy costs. A systematic review and meta-analysis of cost-effectiveness studies found that most analyses, 13 out of 15 for annual FIT and 5 out of 6 for biennial FIT, showed FIT was either cost-saving or very cost-effective compared to colonoscopy every ten years.²⁸ A Japanese microsimulation analysis found annual FIT actually dominated biennial FIT, meaning it cost less overall and produced better health outcomes, because the extra cancers caught earlier by annual testing reduced downstream treatment costs.²⁹

When FIT is used in post-polypectomy surveillance rather than initial screening, the calculus shifts. A UK study estimated that using colonoscopy instead of FIT surveillance to catch one additional cancer cost about £180,778 per extra case detected. For advanced adenomas, the incremental cost was about £7,354 per additional detection.³⁰ That enormous per-case cost for cancer detection via surveillance colonoscopy has led some health systems to consider FIT as an alternative to routine colonoscopy surveillance for lower-risk individuals after polyp removal.

FIT for Symptomatic Patients, Not Just Screening

FIT was developed for screening in people without symptoms, but it has increasingly been adopted by primary care providers to help triage patients who do have symptoms, like changes in bowel habits, abdominal pain, or unexplained weight loss, but whose presentation does not clearly warrant an urgent colonoscopy referral. Two large evaluations of FIT in symptomatic patients in England found strong results. One reported that at a cutoff of 10 micrograms per gram, FIT had 90.5% sensitivity and 91.3% specificity for colorectal cancer, with a negative predictive value of 99.9%. In practical terms, about 10% of tested adults received a positive result, and one in every ten colonoscopies performed on positive patients found cancer.³¹

A separate evaluation in low-risk symptomatic patients in the South West of England reported similar performance: sensitivity of 84%, specificity of 85%, and a negative predictive value of 99.8%.³² That 99.8% to 99.9% negative predictive value is the critical number here: if your FIT comes back negative and your symptoms are not high-risk red flags, the chance you have colorectal cancer is vanishingly small. This has made FIT a useful gatekeeper, allowing GPs to reassure patients and reserve colonoscopy slots for those most likely to benefit.

FIT Beyond Cancer Screening

Researchers have also explored FIT as a monitoring tool for inflammatory bowel disease, particularly ulcerative colitis. Since FIT detects blood from the intestinal lining, it can serve as a proxy for mucosal inflammation. A study of ulcerative colitis patients found that when endoscopy confirmed mucosal healing, FIT was negative in about 73% of those cases, with sensitivity and specificity for detecting mucosal healing around 73% and 82% respectively.³³ A direct comparison with fecal calprotectin, the more established stool biomarker for bowel inflammation, found that FIT predicted mucosal healing in ulcerative colitis about equally well.³⁴ FIT kits are cheaper and more widely available than calprotectin assays, which makes them an appealing alternative for routine monitoring, though this use is still being refined rather than standard practice.

Combining FIT With Other Data

One emerging direction is using machine learning models to combine FIT results with other readily available data, including age, sex, symptoms, and standard blood test results, to improve risk stratification. A decision-curve analysis used several algorithms to classify symptomatic patients and found that a random forest model combining quantitative FIT values with demographics, symptoms, and blood tests achieved an area under the curve of 0.91 for colorectal cancer, with 80% accuracy.³⁵ The idea is that FIT alone is good, but pairing it with information a doctor already has could push the diagnostic accuracy closer to colonoscopy-level performance without requiring the invasive procedure. These approaches are still in the validation stage, but they point toward a future where the stool test your doctor orders is interpreted not in isolation but as one piece of a computational risk profile.